Dova Pharmaceuticals announced that US Food and Drug Administration (FDA) has given green signal to Doptelet (avatrombopag) prescriptive medicine for the treatment of thrombocytopenia in adult patients affecting with a chronic liver disease.
Doptelet is used to treat low platelet counts in adults affecting with severe liver disease and who are scheduled to undergo a treatment.
With the help of Doptelet, the CLD patients can minimise platelet transfusion prior to a procedure by increasing platelet counts to the target level of greater or equal to 50,000 per microliter and reduce the risk of bleeding.
A through trials of testing and reviewing was conducted by FDA in adults suffering with thrombocytopenia included Two global Phase 3, double-blind, placebo-controlled trials (ADAPT-1 [N=231] and ADAPT-2 [N=204]).
On a daily basis for 5 days the patients were allotted to consume 40 mg/60 mg of avatrombopag depending on their Baseline platelet counts (40 to <50>
Thrombocytopenia is a depletion of platelets in the blood of patients suffering from CLD.
Nearly 70,000 patients with CLD have a platelet count of less than 50,000/µL. Every year these patients require multiple invasive diagnostic and therapeutic procedures that lead to a high risk of bleeding.
Besides, Dova is also working on the evaluation of DOPTELET in the treatment of chemotherapy-induced thrombocytopenia (CIT).
The breakthrough medicine is scheduled to launch in the market in the month of June 2018.
